Compare ADMA Biologics Inc (ADMA) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Roblox Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Roblox Corp trades at $54.42 (market cap $40.60B). The key difference: Roblox Corp is far larger — about 19.1× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | RBLX | |
|---|---|---|
Market Cap | $2.13B | $40.60B |
Sector | Health | Media |
52-Week High | $20.38 | $141.56 |
52-Week Low | $7.60 | $41.30 |
Enterprise Value | $2.20B | $39.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Roblox trades at $56.70, up 2.31% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth to $4.89 billion in 2025 and positive operating cash flow of $1.80 billion, though it remains unprofitable with a -20.69% net margin. Recent earnings beats and analyst consensus of $64.07 price target suggest upside potential, but multiple class action lawsuits filed in July 2026 create significant legal overhang.
While Roblox demonstrates strong user monetization and cash generation, profitability challenges and legal risks weigh on investor sentiment. The stock offers growth exposure but requires careful risk management given the negative earnings profile and ongoing litigation. Analyst optimism appears tempered by fundamental weaknesses and recent legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
